{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:14:01Z","timestamp":1792840441199,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20251955"],"award-info":[{"award-number":["BK20251955"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170166"],"award-info":[{"award-number":["82170166"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the National Cancer Center"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jncc.2026.04.001","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:56:42Z","timestamp":1777319802000},"page":"420-428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter phase II trial (cwCLL-001 trial)"],"prefix":"10.1016","volume":"6","author":[{"given":"Yi","family":"Miao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luomengjia","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongyang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeqin","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonglu","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanning","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jncc.2026.04.001_bib0001","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.jncc.2026.04.001_bib0002","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia: a review","volume":"329","author":"Shadman","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jncc.2026.04.001_bib0003","first-page":"158","article-title":"Efficacy and safety of BTK inhibitor combined with bendamustine and rituximab in the first-line treatment of chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"44","author":"Qin","year":"2023","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"21","key":"10.1016\/j.jncc.2026.04.001_bib0004","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jncc.2026.04.001_bib0005","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jncc.2026.04.001_bib0006","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-Rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"issue":"10232","key":"10.1016\/j.jncc.2026.04.001_bib0007","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.jncc.2026.04.001_bib0008","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood-2024-194593","article-title":"Minimal residual disease-guided combination of Ibrutinib and Venetoclax compared to FCR in untreated patients with CLL of intermediate risk: final results of the eradic trial from the Filo Group","volume":"144","author":"Michallet","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jncc.2026.04.001_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100665","article-title":"AMPLIFY: a second-generation BTK inhibitor for fixed-duration therapy in chronic lymphocytic leukemia","volume":"6","author":"Molica","year":"2025","journal-title":"Med"},{"issue":"2","key":"10.1016\/j.jncc.2026.04.001_bib0010","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.001_bib0011","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41408-023-00890-y","article-title":"Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia\/small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort","volume":"13","author":"Miao","year":"2023","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.jncc.2026.04.001_bib0012","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1038\/s41375-021-01280-8","article-title":"Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations","volume":"35","author":"Jain","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jncc.2026.04.001_bib0013","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2352-3026(19)30104-8","article-title":"Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial","volume":"6","author":"Davids","year":"2019","journal-title":"Lancet Haematol"},{"issue":"15","key":"10.1016\/j.jncc.2026.04.001_bib0014","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1182\/bloodadvances.2022009594","article-title":"A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial","volume":"7","author":"Michallet","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jncc.2026.04.001_bib0015","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","article-title":"Orelabrutinib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.jncc.2026.04.001_bib0016","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/ajh.26826","article-title":"Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma patients: multi-center, single-arm, open-label, phase 2 study","volume":"98","author":"Xu","year":"2023","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"10.1016\/j.jncc.2026.04.001_bib0017","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1182\/blood-2021-146491","article-title":"Orelabrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: updated long term results of phase II study","volume":"138","author":"Xu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jncc.2026.04.001_bib0018","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.omto.2021.03.015","article-title":"Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma","volume":"21","author":"Yu","year":"2021","journal-title":"Mol Ther Oncolytics"},{"issue":"12","key":"10.1016\/j.jncc.2026.04.001_bib0019","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jncc.2026.04.001_bib0020","first-page":"S151","article-title":"Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study","volume":"215923","author":"Goede","year":"2018","journal-title":"EHA Learn Cent"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.001_bib0021","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1182\/blood-2015-03-634394","article-title":"Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia","volume":"127","author":"Byrd","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jncc.2026.04.001_bib0022","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/cyto.b.22170","article-title":"Performance of a novel eight-color flow cytometry panel for measurable residual disease assessment of chronic lymphocytic leukemia","volume":"106","author":"Chen","year":"2024","journal-title":"Cytometry B Clin Cytom"},{"issue":"4","key":"10.1016\/j.jncc.2026.04.001_bib0023","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdy021","article-title":"Genetic landscape of ultra-stable chronic lymphocytic leukemia patients","volume":"29","author":"Raponi","year":"2018","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.jncc.2026.04.001_bib0024","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41375-017-0007-7","article-title":"ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation","volume":"32","author":"Malcikova","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.jncc.2026.04.001_bib0025","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41416-019-0502-x","article-title":"The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia","volume":"121","author":"Visentin","year":"2019","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.jncc.2026.04.001_bib0026","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"B\u00f6ttcher","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jncc.2026.04.001_bib0027","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jncc.2026.04.001_bib0028","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.jncc.2026.04.001_bib0029","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jncc.2026.04.001_bib0030","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41375-019-0554-1","article-title":"Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study","volume":"34","author":"Bosch","year":"2020","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.jncc.2026.04.001_bib0031","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1182\/blood-2023-188084","article-title":"Ibrutinib, fludarabine, cyclophosphamide and obinutuzumab (iFCG) for firstline treatment of patients with CLL with mutated IGHV and without Del (17p)\/TP53 mutation: six-year follow-up analyses","volume":"142","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.jncc.2026.04.001_bib0032","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1158\/1078-0432.CCR-22-2779","article-title":"Outcomes in patients with high-risk features after fixed-duration Ibrutinib plus Venetoclax: phase II CAPTIVATE study in first-line chronic lymphocytic leukemia","volume":"29","author":"Allan","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jncc.2026.04.001_bib0033","first-page":"PF572","article-title":"Measurable residual disease kinetics with fixed-duration acalabrutinib-venetoclax combinations in treatment-naive chronic lymphocytic leukemia: data from the phase 3 AMPLIFY trial","volume":"4159979","author":"Ghia","year":"2025","journal-title":"EHA Libr"},{"issue":"23","key":"10.1016\/j.jncc.2026.04.001_bib0034","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"36","key":"10.1016\/j.jncc.2026.04.001_bib0035","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1200\/JCO.21.01181","article-title":"Minimal residual disease dynamics after venetoclax-Obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study","volume":"39","author":"Al-Sawaf","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jncc.2026.04.001_bib0036","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s11864-023-01103-1","article-title":"Measurable residual disease in chronic lymphocytic leukemia: current understanding and evolving role in clinical practice","volume":"24","author":"Rios-Olais","year":"2023","journal-title":"Curr Treat Options Oncol"},{"issue":"13","key":"10.1016\/j.jncc.2026.04.001_bib0037","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1182\/bloodadvances.2022007378","article-title":"High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse","volume":"6","author":"Short","year":"2022","journal-title":"Blood Adv"},{"issue":"18","key":"10.1016\/j.jncc.2026.04.001_bib0038","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jncc.2026.04.001_bib0039","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.amjcard.2015.05.045","article-title":"Economic burden of undiagnosed nonvalvular atrial fibrillation in the United States","volume":"116","author":"Turakhia","year":"2015","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.jncc.2026.04.001_bib0040","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3390\/cancers17050907","article-title":"Molecular mechanisms in the transformation from indolent to aggressive B cell malignancies","volume":"17","author":"Maher","year":"2025","journal-title":"Cancers"}],"container-title":["Journal of the National Cancer Center"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667005426000554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667005426000554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T11:48:30Z","timestamp":1786880910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667005426000554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2667005426000554"],"URL":"https:\/\/doi.org\/10.1016\/j.jncc.2026.04.001","relation":{},"ISSN":["2667-0054"],"issn-type":[{"value":"2667-0054","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter phase II trial (cwCLL-001 trial)","name":"articletitle","label":"Article Title"},{"value":"Journal of the National Cancer Center","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jncc.2026.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Chinese National Cancer Center. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}